Because leukemia classification and prognosis stratification are complex, there is no one-size-fits-all treatment method, and it is necessary to combine careful classification and prognosis stratification to formulate treatment plans. At present, there are mainly the following types of treatment methods: chemotherapy, radiotherapy, targeted therapy, immunotherapy, stem cell transplantation, etc.
Through reasonable comprehensive treatment, the prognosis of leukemia has been greatly improved. A considerable number of patients can be cured or long-term stable. The era of leukemia as an “incurable disease” has passed.
AML treatment (non-M3)
M3 treatment
ALL treatment
Chronic Myelogenous Leukemia Treatment
Chronic lymphocyte therapy
Treatment of central nervous system leukemia
Although the types of M4 and M5 in ALL and AML are often combined with CNSL, other acute leukemias can also occur. Because commonly used drugs are difficult to penetrate the blood-brain barrier, these patients usually need lumbar puncture to prevent and treat CNSL. Some refractory patients may require whole-brain spinal cord radiotherapy.
Except for a few special patients who may benefit from autologous transplantation (the autologous transplantation recurrence rate is very high), the vast majority of leukemia patients should choose xenotransplantation for transplantation.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
- Susan Hauhttps://cancerfax.com/author/susan/
- Susan Hauhttps://cancerfax.com/author/susan/
- Susan Hauhttps://cancerfax.com/author/susan/
- Susan Hauhttps://cancerfax.com/author/susan/